Clinical Trial Agreement: What companies should clarify before study start

Key takeaways

• A Clinical Trial Agreement governs the cooperation between the sponsor, trial site and investigator in a clinical trial. 

• It brings together the study protocol, regulatory requirements, operational processes and commercial interests. 

• Clear provisions on responsibilities, compensation, data protection, study data, IP, publications, liability and compliance are particularly important. 

• For medicinal product trials in Germany, the standard contractual clauses under Section 42d AMG and the StandVKlV may be relevant. 

• A CTA should always be reviewed together with the protocol, budget, data protection documents and overall study set-up. 

Why is a Clinical Trial Agreement so important?

A clinical trial does not begin with the recruitment of the first participant. Long before that, the parties need to clarify who assumes which role, which services are owed, which regulatory obligations apply and how the cooperation will work in practice.

This is the purpose of the clinical trial agreement, commonly referred to as a Clinical Trial Agreement or CTA. It provides the legal basis for the cooperation between the sponsor, the trial site, the investigator and, where relevant, further parties involved in the study.

The sponsor will typically develop the study concept, provide funding and the investigational medicinal product and assume overall regulatory responsibility. The trial site provides personnel, infrastructure and medical expertise, while the investigator conducts the study at the site and assumes professional and medical responsibility for that conduct.

The CTA does not replace the applicable regulatory framework. Rather, it translates that framework into the practical cooperation between the parties. For clinical trials with medicinal products, the relevant framework will typically include Regulation (EU) No. 536/2014, the German Medicinal Products Act, ICH-GCP, the Declaration of Helsinki and data protection law.

What does a Clinical Trial Agreement cover?

A Clinical Trial Agreement governs the conduct of a clinical trial at the trial site. In the classic set-up, it is the agreement between the sponsor and the trial site. Depending on the study structure, the investigator, additional departments or clinical research organisations (CROs) may also be involved.

At its core, the CTA defines which services the trial site will provide, which obligations remain with the sponsor and how the protocol will be implemented at operational level. Typical subject matters include:

1. conduct of the trial and recruitment; 

2. responsibilities of sponsor, trial site and investigator; 

3. investigational medicinal product, investigational device, equipment and materials; 

4. documentation, monitoring, audits and inspections; 

5. compensation, payment mechanics and additional services; 

6. data protection and handling of health data; 

7. study data, results, IP and publications; 

8. confidentiality and use of names and trademarks; 

9. compliance; 

10. insurance and liability; 

11. termination and early discontinuation. 

The protocol remains the key scientific document of the study. It describes how the study is to be conducted from a medical and scientific perspective. The CTA, by contrast, describes how the parties will implement those requirements legally, commercially and operationally.

Both documents therefore need to align. Amendments to the protocol may have direct consequences for compensation, monitoring, documentation, data flows and resource planning. Conversely, unclear contractual provisions can significantly complicate the practical conduct of the study.

Practical note: Protocol, budget, data protection agreement and CTA should be reviewed in parallel. Changes to one document will often affect the others.

Which operational obligations matter most?

Every CTA starts with the conduct of the study at the trial site. The agreement should clearly set out which services the trial site will provide, which qualifications and resources are required and which rules apply to recruitment, visits, examinations and documentation.

Recruitment deserves particular attention. A trial site will usually not be able to guarantee a specific number of participants, since inclusion criteria, medical suitability, patient availability and willingness to consent cannot be fully controlled. The better approach is to work with realistic assumptions, reporting obligations and escalation mechanisms if recruitment targets are not met. In multicentre trials, the agreement should also clarify whether recruitment is site-specific or competitive.

The handling of the investigational medicinal product, investigational device, software, equipment and materials should also be addressed. This includes delivery, storage, use, documentation, return and destruction. For medical devices, additional points may arise, such as training, instructions for use, accessories, software and technical documentation.

Monitoring, audits and inspections should be structured in a way that satisfies regulatory requirements without unnecessarily disrupting clinical operations.

What should be considered for compensation and compliance?

Problems often arise not because the compensation is too high or too low, but because the budget, the protocol and operational reality are not sufficiently aligned.

A robust budget should make clear which services are compensated and which services are already included. Typical compensation items include start-up fees, visits, screening failures, drop-outs, documentation, queries, close-out, archiving and study-related ancillary services, for example pharmacy, radiology or laboratory services.

Protocol amendments require particular attention. They may trigger additional visits, further examinations, changed documentation obligations or longer study timelines. The agreement should therefore specify when a budget adjustment is required and how it is to be agreed.

Compliance is not limited to the appropriateness of compensation. Payment structures must be designed so that they cannot be understood as an inducement for prescribing, purchasing or sales decisions. Separation principle, equivalence principle, fair market value, transparency requirements and internal approval processes therefore remain important.

At the same time, the agreement must ensure that the study only starts once the required regulatory approvals and ethics committee opinion are in place, that AMG, EU CTR, GCP and data protection requirements are complied with and that safety reporting, insurance, pharmacovigilance, audits, inspections and SOPs fit with the contractual obligations.

How do IP, study data and publications interact?

The treatment of study data, results, inventions and publications is one of the key negotiation points in any CTA. Different interests meet here: the sponsor wants to use the results for regulatory, commercial and scientific purposes, while trial sites and investigators have a legitimate interest in scientific publication, research and teaching.

From the sponsor’s perspective, the study data must be usable for marketing authorisation applications, conformity assessments, regulatory communications, product development and later commercial exploitation. The agreement should therefore make clear to what extent the sponsor receives access to study data, which use rights are granted and whether those rights also cover affiliates, CROs, licensees or acquirers of a product.

The agreement should also distinguish between different categories of results. Pre-existing know-how and background IP will usually remain with the relevant party. Results generated in accordance with the contract and protocol are often allocated to the sponsor or made available to the sponsor under broad use rights. For protectable inventions, the agreement should additionally regulate who receives invention disclosures, who may file for protection, whether the sponsor has an option right and how any inventor remuneration is dealt with.

From the trial site’s perspective, scientific integrity, publication freedom and the ability to use findings for non-commercial research are central. These interests should not be excluded across the board. A common solution is a staged process: the trial site may publish results, but must submit planned publications to the sponsor in advance. The sponsor may require the removal of confidential information, provide factual comments and postpone publication for a limited period if this is necessary to protect patent rights.

In multicentre studies, the sponsor will often have a legitimate interest in coordinating the first publication of the overall study results. Individual site publications may affect the scientific value of the overall study or interfere with regulatory strategy. The CTA should therefore specify when site-specific publications are permitted and how long the trial site must wait for a multicentre publication.

The clauses must also work together. A broad confidentiality clause must not make publication rights illusory. An IP clause must not inadvertently capture the trial site’s background IP. Conversely, publication rights must not lead to the disclosure of confidential information or jeopardise patent filings. A good CTA does not resolve these tensions through blunt priority rules, but through clear definitions, review periods, deferral rights and purpose-specific use rights.

How is data protection addressed in the CTA?

Clinical trials regularly involve the processing of health data. Data protection is therefore not an ancillary issue, but a core element of the study structure.

The detailed data protection arrangements are often not fully set out in the CTA itself. They are usually addressed in separate data protection agreements, participant information sheets and consent documents. Depending on the allocation of roles, an arrangement on joint controllership under Article 26 GDPR may be relevant. A data processing agreement under Article 28 GDPR will only be appropriate where one party processes personal data on behalf of, and under the instructions of, another party.

The CTA should at least describe the basic data protection structure and refer to the relevant data protection documents. In international studies, further issues arise, including third-country transfers, intra-group data flows, central databases, remote monitoring, cloud services and access by CROs.

How should liability, insurance and termination be addressed?

Liability provisions must reflect the actual allocation of risk. Clinical trials may create risks for participants, trial sites and sponsors. The agreement should therefore clarify who is responsible for which breaches, damages and claims.

Several levels need to be distinguished. First, there is the insurance cover for trial participants required by law or regulation. Second, there is the liability of the parties as between themselves. Third, indemnities may be required, for example for claims arising from the investigational medicinal product, investigational device, protocol or sponsor-driven instructions.

The trial site should not be responsible for risks it cannot control. Conversely, the sponsor will expect the trial site to remain responsible for its own breaches, inaccurate documentation, unauthorised protocol deviations or violations of regulatory requirements.

Termination and early discontinuation should also be regulated in more than formal terms. Clinical trials may end early because of safety concerns, ethical reasons, regulatory orders, insufficient recruitment, strategic decisions by the sponsor or serious contractual breaches.

In that event, the agreement should specify in particular that no further participants will be recruited, that participants already enrolled will be informed and medically cared for as appropriate, that regulatory notifications will be made, that investigational medicinal products or devices will be returned or destroyed and that services already rendered will be compensated. Early termination often reveals whether the agreement only covers the normal case or also provides workable mechanisms for crisis situations.

Which contractual structures are possible?

The term Clinical Trial Agreement does not describe one uniform type of contract. The appropriate structure depends on who initiates the study, who acts as regulatory sponsor, which services are provided at the trial site and which further service providers are involved.

In sponsor-initiated trials, the sponsor develops the protocol, funds the study and assumes regulatory responsibility. The trial site conducts the study at the site in accordance with the protocol. In this set-up, the CTA forms the interface between regulatory responsibility and practical study conduct.

In investigator initiated trials, or IITs, the scientific initiative often lies with the investigator or a research institution. Responsibilities for study planning, funding, data management, publication and use of results may therefore shift significantly. A template designed for sponsor-initiated trials should not be transferred to IITs without careful review.

Medical device investigations also have specific features. Many contractual issues are similar to those in medicinal product trials, but the regulatory references, terminology and product-related obligations differ. MedTech companies should therefore not apply medicinal-product CTA templates mechanically.

What role do CRO agreements play?

CRO agreements must be distinguished from Clinical Trial Agreements with trial sites. In practice, CROs do not only provide monitoring, data management, project management or pharmacovigilance. Depending on the mandate, they may also support study strategy, site selection, patient recruitment, regulatory submissions, data analytics, decentralised trial elements, technology platforms, market access or the coordination of international study networks.

Many CROs therefore function in practice as outsourced development and study infrastructure. That does not change the legal structure. The CRO agreement governs the service relationship between sponsor and CRO. The CTA, by contrast, governs the conduct of the clinical trial at the trial site and remains necessary.

Nor does the involvement of a CRO fully shift the sponsor’s regulatory responsibility. The sponsor may delegate tasks, but will typically remain responsible for ensuring that the study is properly organised, supervised and conducted in a way that is regulatory-compliant. CRO agreement, CTA, protocol, data protection structure and operational communication channels therefore need to be carefully aligned.

This is particularly important where the CRO acts as the primary day-to-day contact for the trial site. In that case, the documents should make clear which statements the CRO may make, which information it may receive, how monitoring and audits are conducted, who coordinates payments and which decisions remain reserved to the sponsor.

What is specific to Germany?

In Germany, contract negotiations for clinical trials with medicinal products are intended to become faster and more uniform, particularly for contracts concluded after 17 December 2025 that fall within the scope of the Standard Contractual Clauses Regulation, the StandVKlV. The reason is practical: sponsors and trial sites often negotiate the same areas repeatedly, including archiving, audits, confidentiality, publications, data protection, work results, liability and termination.

Section 42d AMG and the StandVKlV address this by introducing standard contractual clauses. These are pre-formulated model clauses for certain recurring rights and obligations of sponsors and trial sites. They are intended to structure typical negotiation points without turning into a complete contract template for every clinical trial.

For contracts within scope, sponsor and trial site are required to use the standard contractual clauses unless they agree to deviate from them. The clauses are therefore not mandatory contractual content in the sense of being immutable. They are a statutory default model with an express contractual opt-out. Clinical trials initiated by a non-commercial sponsor without a commercial purpose are not covered by this regime.

For practice, this means that the model clauses are useful, but not sufficient on their own. Study-specific services, budget, operational processes, special IP issues, ancillary services, data protection documents and the involvement of further service providers must still be addressed individually.

Practical note: The StandVKlV can significantly structure contract negotiations. It does not replace the review of the specific study, its allocation of roles and its operational particularities.

The practical application, scope and limits of the StandVKlV deserve separate consideration. We will address these points in a dedicated article.

How should companies prepare CTA negotiations?

A short preparation process is usually helpful:

1. Clarify roles. Who is the sponsor, trial site, investigator, CRO, laboratory, biobank or other service provider? 

2. Review protocol and contract in parallel. Protocol changes may affect compensation, services, monitoring, data flows and archiving. 

3. Involve data protection early. Role allocation, consent documents, third-country transfers and service provider access should be clarified before signature. 

4. Pre-negotiate IP and publications. Especially with academic centres, data rights, use of results and publication processes should be addressed early. 

5. Review the compliance structure. Compensation and payment flows must be appropriate and transparent. Equally, the agreement should connect regulatory approvals, ethics committee opinion, AMG and EU CTR requirements, GCP, data protection, pharmacovigilance, insurance and internal SOPs with the practical conduct of the study. 

6. Align ancillary documents. Data protection agreements, quality agreements, SOPs, insurance certificates, annexes and budget must fit together. 

What should companies do now?

A clinical trial agreement is more than a formality before study start. It helps determine whether a study can be conducted efficiently, in a regulatory-compliant manner and on a commercially sound basis.

Companies should assess early which contractual structure applies, which parties need to be involved and which documents belong together. Clear provisions on responsibilities, services, compensation, compliance, data protection, study data, IP, publications, confidentiality, liability and termination are particularly important.

For medicinal product trials in Germany, companies should also assess whether Section 42d AMG and the StandVKlV are relevant. For medical device investigations and IITs, the applicable regulatory requirements, allocation of roles and documentation obligations should be reviewed separately.